Flares in lupus nephritis: Incidence, impact on renal survival and management

Lupus

Volumn 7, Issue 9, 1998, Pages 635-638

  Ponticelli, C ^a   Moroni, G ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

Autoimmune diseases; Corticosteroids; Immunosuppression; Lupus nephritis

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE;

ASEPTIC NECROSIS; DISEASE COURSE; DISEASE SEVERITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY DISEASE; KIDNEY FAILURE; LUPUS ERYTHEMATOSUS NEPHRITIS; OVARY DISEASE; PRIORITY JOURNAL; PROGNOSIS; PULSATILE DRUG RELEASE; REMISSION; SHORT SURVEY; SYSTEMIC LUPUS ERYTHEMATOSUS; VIRUS INFECTION;

FOLLOW-UP STUDIES; HUMANS; INCIDENCE; LUPUS NEPHRITIS; RECURRENCE; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE;

EID: 0032418157     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/096120398678920776     Document Type: Short Survey

References (18)

1. Donadio JV, Holley KE, Ferguson RU, Ilstrup DM. Treatment of diffuse proliferative lupus nephritis with prednisone and combined prednisone and cyclophosphamide. N Engl J Med 1978; 299: 1151-1155.
2. Chan TM et al Sequential therapy for diffuse proliferative and membranous lupus nephritis: cyclophosphamide and prednisolone followed by azathioprine and prednisolone. Nephron 1995; 71: 321-327.
3. Ciruelo E, De la Cruz J, Lopez I, Gomez-Reino JJ. Cumulative rate of relapse of lupus nephritis after successful treatment with cyclophosphamide. Arthritis Rheum 1996; 39: 2028-2034.
4. Boumpas DT et al Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992; 340: 741-745.
5. Moroni G et al 'Nephritic flares' are predictors of bad long-term renal outcome in lupus nephritis. Kidney Int 1996; 50: 2047-2053.
6. Leaker B, Fairley KF, Dowling J, Kincaid-Smith P. Lupus nephritis: clinical and pathological correlation. Q J Med 1987; 62: 163-179.
7. Wagner-Weiner I, Magilavy DB, Emery HM. Flare of childhood lupus nephritis after discontinuing treatment with intravenous pulse cyclophosphamide. Arthritis Rheum 1988; 31 (Suppl. 4): abstract 102.
8. Moroni G, Banfi G, Ponticelli C. Clinical status of patients after 10 years of lupus nephritis. Q J Med 1992; 84: 681-689.
9. Chagnac A et al Outcome of the acute glomerular injury in proliferative lupus nephritis. J Clin Invest 1989; 84: 922-930.
10. Pollak VE, Kant KS, Hariharan S. Diffuse and focal proliferative lupus nephritis: treatment approach and results. Nephron 1991; 59: 177-193.
11. Ponticelli C. Treatment of lupus nephritis. The advantages of a flexible approach. Nephrol Dial Transplant 1997; 12: 2057-2059.
12. Esdaile JM et al The time-dependence of long-term prediction in lupus nephritis. Arthritis Rheum 1994; 37: 359-368.
13. Gourley MF et al Methylprednisolone and cyclophosphamide alone or in combination, in patients with lupus nephritis. Ann Intern Med 1996; 125: 549-557.
14. Ponticelli C. Current treatment recommendations for lupus nephritis. Drugs 1990; 40: 19-30.
15. Lloyd W, Shur PH. Immune complexes, complement, and anti-DNA in exacerbations of systemic lupus erythematosus (SLE). Medicine 1981; 60: 208-217.
16. Coremans EM et al Changes in antibodies to C1q predict renal relapses in systemic lupus erythematosus. Am J Med 1995; 26: 595-601.
17. ter Borg EJ et al Measurement of increase in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus, a long-term, prospective study. Arthritis Rheum 1990; 33: 634-643.
18. Swaak AJG, Aarden LA, Statius van Eps LW, Feltkamp TEW. Anti-dsDNA and complement profiles as prognostic guides in systemic lupus erythematosus. Arthritis Rheum 1979; 22: 226-235.